
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PENAO,Sirolimus
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : PENAO Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
Details : This next-generation adenine nucleotide translocase (ANT) inhibitor, PENAO, was shown to be safe and well-tolerated in a phase I clinical trial conducted in Australia where encouraging efficacy data was observed.
Product Name : PENAO
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : PENAO,Sirolimus
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : PENAO Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement
